Side-by-side financials for ALT and ABBV. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ALT | ABBV |
|---|---|---|
| Market cap | - | $400.96 B |
| US-listed rank | - | #31 |
| Revenue (latest FY) | $41.00K | $61.16B |
| Net income (latest FY) | -$88.09M | $4.23B |
| Net margin | -214861.0% | 6.9% |
| P/E (trailing FY) | - | 94.9 |
| SEC filings | 997 | 1,008 |
In their latest fiscal years, Altimmune, Inc. reported $41.00K in revenue while AbbVie Inc. reported $61.16B.
Full pages: Altimmune, Inc. and AbbVie Inc., or browse the full rankings.